Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
20,317 results
- Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis: Complete Statistical AnalysisIndependent statistical analysis of Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis: Complete Statistical AnalysisIndependent statistical analysis of Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02039401).
- Safety Study of XP12B in Women With Menorrhagia: Complete Statistical AnalysisIndependent statistical analysis of Safety Study of XP12B in Women With Menorrhagia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00113568).
- Safety Study That Compares Perlane to Perlane With Lidocaine (Perlane-L) While Correcting Wrinkles in the Area Around Your Nose: Complete Statistical AnalysisIndependent statistical analysis of Safety Study That Compares Perlane to Perlane With Lidocaine (Perlane-L) While Correcting Wrinkles in the Area Around Your Nose: primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital: Complete Statistical AnalysisIndependent statistical analysis of Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy: Complete Statistical AnalysisIndependent statistical analysis of Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying…
- Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos: Complete Statistical AnalysisIndependent statistical analysis of Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01396434).
- Safety Trial of the RedDress Wound Care System (RD1) in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.: Complete Statistical AnalysisIndependent statistical analysis of Safety Trial of the RedDress Wound Care System (RD1) in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.: primary endpoint results, effect estimate with confidence interval,…
- Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors: Complete Statistical AnalysisIndependent statistical analysis of Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age: Complete Statistical AnalysisIndependent statistical analysis of Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea: Complete Statistical AnalysisIndependent statistical analysis of Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder: Complete Statistical AnalysisIndependent statistical analysis of Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease: Complete Statistical AnalysisIndependent statistical analysis of Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Efficacy, and Pharmacokinetics of SKY0402 Administered as a Nerve Block in Subjects Undergoing Bunionectomy: Complete Statistical AnalysisIndependent statistical analysis of Safety, Efficacy, and Pharmacokinetics of SKY0402 Administered as a Nerve Block in Subjects Undergoing Bunionectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Efficacy, and Side Effects Study of Interventional Cryotherapy in the Pleural Space(“ICE PLS”): Complete Statistical AnalysisIndependent statistical analysis of Safety, Efficacy, and Side Effects Study of Interventional Cryotherapy in the Pleural Space("ICE PLS"): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH: Complete Statistical AnalysisIndependent statistical analysis of Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH: primary endpoint results, effect estimate with confidence interval,…
- Safety, Efficacy, Longitudinal Costs and Patient-Centered Outcomes Using a TAAA Debranching Device: Complete Statistical AnalysisIndependent statistical analysis of Safety, Efficacy, Longitudinal Costs and Patient-Centered Outcomes Using a TAAA Debranching Device: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants: Complete Statistical AnalysisIndependent statistical analysis of Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1: Complete Statistical AnalysisIndependent statistical analysis of Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.: Complete Statistical AnalysisIndependent statistical analysis of Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali: Complete Statistical AnalysisIndependent statistical analysis of Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali:…
- Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older: Complete Statistical AnalysisIndependent statistical analysis of Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008): Complete Statistical AnalysisIndependent statistical analysis of Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate: Complete Statistical AnalysisIndependent statistical analysis of Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00319228).
- Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients: Complete Statistical AnalysisIndependent statistical analysis of Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02927366).
- Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB): Complete Statistical AnalysisIndependent statistical analysis of Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411: Complete Statistical AnalysisIndependent statistical analysis of Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04101357).
- Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease): Complete Statistical AnalysisIndependent statistical analysis of Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV): Complete Statistical AnalysisIndependent statistical analysis of Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza: Complete Statistical AnalysisIndependent statistical analysis of Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix: Complete Statistical AnalysisIndependent statistical analysis of Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix:…
- Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029): primary endpoint results, effect estimate with…
- Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants.: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04488770).
- Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects: primary…